21364-46-5 Usage
Uses
Used in Pharmaceutical Industry:
Isoquinolinium chloride is used as a pharmaceutical intermediate for the synthesis of various organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Alzheimer's Disease Treatment:
Isoquinolinium chloride is used as a cholinesterase inhibitor for its potential implications in the treatment of Alzheimer's disease, helping to improve cognitive function and slow disease progression.
Used in Pain Management:
Isoquinolinium chloride is used as an analgesic agent, providing pain relief and managing discomfort in various medical conditions.
Used in Seizure Control:
Isoquinolinium chloride is used as an anticonvulsant, helping to prevent and control seizures in patients with epilepsy and other seizure disorders.
Used in Organic Synthesis:
Isoquinolinium chloride is used as a catalyst in organic reactions, facilitating and enhancing the efficiency of chemical processes in the synthesis of various compounds.
Used in Electrochemical Industry:
Isoquinolinium chloride is used as a stabilizer in the electrochemical industry, ensuring the stability and performance of electrochemical systems and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 21364-46-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,3,6 and 4 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 21364-46:
(7*2)+(6*1)+(5*3)+(4*6)+(3*4)+(2*4)+(1*6)=85
85 % 10 = 5
So 21364-46-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H7N.ClH/c1-2-4-9-7-10-6-5-8(9)3-1;/h1-7H;1H
21364-46-5Relevant academic research and scientific papers
5-HETERO-OR ARYL-SUBSTITUTED-IMIDAZO(2,1-A)ISOQUINOLINES AND THEIR USE AS PAF RECEPTOR ANTAGONISTS
-
, (2008/06/13)
The invention discloses certain 5-hetero or aryl-substituted-imidazo[2, 1-a]isoquinolines useful as platelet activating factor (PAF) receptor antagonists, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-mediated bronchoconstriction and extravassation and PAF-mediated, endotoxin-induced lung injury, and for controlling hyperreactive airways induced by PAF or allergin. In addition, the invention discloses the use of a select group of said compounds as anti-tumor agents.
